|Articles|July 28, 2009
Retina Roundtable Session 3
Advertisement
Subscribe
In this third session, the physicians discuss how they communicate to their patients the increased risk of stroke that may be associated with dosing of anti-VEGF agents.
Participants include:
Return to
Return to
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
3
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
4
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
5














































.png)


